Extended Data Table 3 Baseline demographics and disease characteristics in response-evaluable patients (n = 101) and additional treated patients (n = 47) with MSS mCRC

From: Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial